PDCD1 and neoplasm: Based on the rationale described, several clinical trials of combination therapy with pembrolizumab, a PD-1 antibody, with chemotherapy and trastuzumab were conducted in USA and countries in Asia, demonstrating higher ORR and tumor burden reduction [24,25,26].